APOLIPOPROTEIN B, PCSK9 INHIBITION WITH ALIROCUMAB, AND ISCHEMIC CARDIOVASCULAR EVENTS AFTER ACUTE CORONARY SYNDROME: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL

Autor:	Shaun G. Goodman, Gregory G. Schwartz, Jennifer McGinniss, Evangelos Liberopoulos, Deepak L. Bhatt, Matthew T. Roe, Nicolas Danchin, Andreas M. Zeiher, Robert A. Harrington, Nikolaus Marx, Michael Szarek, Emil Hagström, Vera Bittner, Rafael Diaz, Harvey D. White, Johan Wouter Jukema, Philippe Gabriel Steg, Yong-Un Kim, Michael J. Louie
Rok vydání:	2020
Předmět:	medicine.medical_specialty Acute coronary syndrome Apolipoprotein B biology business.industry PCSK9 medicine.disease Endocrinology Atherogenic lipoprotein Internal medicine medicine biology.protein lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business Alirocumab Lipoprotein
Zdroj:	Journal of the American College of Cardiology. 75:75
ISSN:	0735-1097
DOI:	10.1016/s0735-1097(20)30702-6
Popis:	Apolipoprotein B (Apo B) provides an integrated measure of atherogenic lipoprotein particles including, but not limited to, low-density lipoprotein (LDL). Apo B was measured in 18,924 patients with recent acute coronary syndrome (ACS) and elevated atherogenic lipoprotein levels (e.g. LDL
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5789a877df74236762fa18f8e3eebb9e https://doi.org/10.1016/s0735-1097(20)30702-6 Zobrazit plný text záznamu